The research team, led by investigators at Shandong University and collaborating institutions across China, set out to answer a question that has puzzled oncologists for years: how do colorectal cancer cells that survive chemotherapy manage to keep their mitochondria, the cellular power plants, in working order? Drug-tolerant persister cells are known to enter a reversible adaptive state, rather than acquiring permanent genetic resistance mutations, which makes them especially insidious. When therapy stops, these cells can resume proliferation and regenerate the tumor with its original drug sensitivity intact. The researchers built a comprehensive experimental system to catch these cells in the act, using patient-derived xenografts, organoids grown from patient tumors, conventional colorectal cancer cell lines, and cell line-derived xenografts in animal models.

What they observed in the surviving cells was a profound metabolic transformation. The persister cells showed markedly reduced proliferation without a corresponding increase in apoptosis, the programmed cell death that chemotherapy is designed to trigger. When the researchers withdrew the drugs, the cells resumed growth, confirming that the tolerant state was genuinely reversible. At the metabolic level, the persister cells suppressed glycolysis, the sugar-burning pathway that most cancer cells rely on heavily, and produced far less lactate, the acidic byproduct of that pathway. Instead, they became increasingly dependent on oxidative phosphorylation, the more efficient mitochondrial process that generates cellular energy using oxygen. This metabolic shift was accompanied by a striking activation of mitophagy, the cellular quality-control system that selectively recycles damaged mitochondria.

The centerpiece of the discovery is a protein called UQCRC2, or ubiquinol-cytochrome c reductase core protein 2, a structural component of complex III in the mitochondrial electron transport chain. The researchers found that UQCRC2 accumulated in the drug-tolerant persister cells, where it supported Parkin and SQSTM1-associated mitophagy and enabled the residual cells to survive. But the truly novel element lies in how UQCRC2 is regulated. The team employed an emerging field of post-translational modification research known as lactylomics, using global mass-spectrometry-based profiling to map lysine lactylation sites, a chemical tagging process in which lactate-derived lactyl groups attach to lysine residues on proteins. Because the persister cells produced less lactate, the overall level of lysine lactylation across the proteome dropped, and specifically, lactylation of UQCRC2 at the amino acid lysine 430 declined sharply.

Here the story takes a turn worthy of a molecular thriller. When UQCRC2 is heavily lactylated at position 430, the modified protein becomes a target for K48-linked ubiquitination, a molecular tag that condemns proteins to destruction by the proteasome, the cell’s waste-disposal machinery. Reduced lactylation therefore protects UQCRC2 from degradation and allows it to accumulate. The researchers identified the enzyme responsible for removing the lactyl tag: SIRT1, a member of the sirtuin family of NAD-dependent deacylases that has long been associated with longevity, stress resistance, and metabolic regulation. Through a cell-free delactylation assay, the team demonstrated that SIRT1 directly removes the lactylation from UQCRC2 at lysine 430 in a manner dependent on NAD, the cellular energy carrier. This delactylation stabilizes UQCRC2, preserving mitochondrial function and fueling the mitophagy program that keeps the persister cells alive.

The functional consequences of this pathway were confirmed through a series of genetic and pharmacological experiments. When the researchers depleted PINK1, the kinase that initiates the mitophagy cascade, or knocked down UQCRC2 itself, the survival of the residual drug-tolerant cells plummeted and tumor regrowth was significantly delayed. Inhibiting SIRT1, either genetically or with drugs, produced the same effect, effectively collapsing the survival mechanism that the persister cells depend upon. These results suggest that the SIRT1-UQCRC2 axis represents a genuine therapeutic vulnerability, a chink in the armor of chemotherapy-tolerant cells that could be exploited to prevent the outgrowth of tumors after treatment.

Perhaps the most clinically significant finding came from analyses of actual patient samples. Among chemotherapy-responsive patients with advanced colorectal cancer, low expression of the UQCRC2-K430 lactylation mark in tumor tissue remained associated with poorer overall survival even after multivariable statistical adjustment. The researchers also examined paired samples of circulating tumor cells, rare cancer cells that travel through the bloodstream, collected from patients before and after chemotherapy exposure. In these paired samples, increased SIRT1 expression or decreased UQCRC2-K430 lactylation after chemotherapy was associated with shorter progression-free survival. This pattern suggests that the molecular signature of the persister state, detectable in a simple blood-based assay, could serve as an early warning system identifying patients whose residual disease is primed for relapse.

The methodological breadth of the study deserves particular attention. By integrating whole-exome sequencing with transcriptomic, proteomic, metabolomic, and lactylomic analyses, the researchers were able to triangulate the mechanism from multiple independent angles, ruling out genetic mutation as the driver and instead pointing to a reversible epiproteomic program. Whole-exome sequencing confirmed that the persister cells had not acquired new resistance mutations, while the multi-omic profiling revealed the coordinated metabolic and post-translational remodeling that defines the tolerant state. Metabolic assays measuring oxygen consumption and extracellular acidification rates quantified the shift from glycolysis to oxidative phosphorylation, while protein stability and ubiquitination analyses traced the fate of UQCRC2 through the degradation pathway.

The broader implications of this work extend well beyond colorectal cancer. Drug-tolerant persister cells have been implicated in treatment failure across many tumor types, and the discovery that lysine lactylation functions as a metabolic sensor linking glycolytic output to mitochondrial quality control provides a unifying framework for understanding how cancer cells weather therapeutic stress. Lactate, long dismissed as a mere metabolic waste product, is increasingly recognized as a signaling molecule, and this study adds a striking new dimension to that picture: lactate levels directly tune the stability of a core respiratory protein, thereby determining whether a cell can maintain the mitochondrial infrastructure needed to survive chemotherapy. The finding also positions sirtuins, and SIRT1 in particular, as enzymatic gatekeepers of this lactylation-dependent survival program, raising the prospect that existing and experimental SIRT1 inhibitors could be repurposed as anti-persister agents.

For patients, the road from laboratory discovery to clinical application is long, but this study offers concrete waypoints. The identification of UQCRC2-K430 lactylation as a candidate biomarker of chemotherapy-associated residual disease opens the door to trials that could monitor this mark in circulating tumor cells during treatment, potentially allowing oncologists to intervene before overt relapse occurs. Therapeutic strategies that combine standard FOLFOXIRI chemotherapy with agents that disrupt the SIRT1-UQCRC2-mitophagy axis could, in principle, eliminate the reservoir of persister cells that currently seed tumor regrowth. As the authors conclude, this low-lactate, SIRT1-regulated mechanism couples metabolic suppression to mitochondrial quality control and enables reversible chemotherapy tolerance, and it now stands as one of the most mechanistically complete portraits of drug tolerance assembled in any cancer type to date. The study was supported by the National Natural Science Foundation of China and multiple Chinese research foundations, and the full open-access article is available in Molecular Cancer.

Subject of Research: Lactylation-mediated mitophagy in colorectal cancer drug tolerance during chemotherapy

Article Title: UQCRC2 lactylation-mediated mitophagy orchestrates colorectal cancer cell metabolism to establish a drug-tolerant state during chemotherapy

Article References: UQCRC2 lactylation-mediated mitophagy orchestrates colorectal cancer cell metabolism to establish a drug-tolerant state during chemotherapy. (n.d.). https://doi.org/10.1186/s12943-026-02793-5

Image Credits: AI Generated

DOI: 10.1186/s12943-026-02793-5

Keywords: colorectal cancer, drug-tolerant persister cells, FOLFOXIRI chemotherapy, UQCRC2, lysine lactylation, SIRT1, mitophagy, oxidative phosphorylation, metabolic reprogramming, circulating tumor cells, chemotherapy tolerance, Molecular Cancer

PFKL is one of the most important regulatory proteins in the pathway that converts glucose into usable cellular energy. Glycolysis takes place in the cytoplasm and breaks one molecule of glucose into two molecules of pyruvate, producing ATP while also generating metabolic intermediates needed to make nucleotides, amino acids and lipids. The reaction controlled by phosphofructokinase is especially significant because it acts as a metabolic checkpoint. Once glucose-derived carbon passes through this stage, the cell is strongly committed to processing it through glycolysis.

Cancer cells frequently alter this pathway. Many tumors consume glucose at unusually high rates even when oxygen is available, a phenomenon historically associated with the Warburg effect. This metabolic reprogramming does not simply provide energy. It gives malignant cells flexible access to the molecular building blocks required for DNA replication, membrane production and rapid division. Because glycolysis is so central to tumor biology, enzymes within the pathway have long attracted attention as possible drug targets. The challenge has been finding a way to interfere with cancer metabolism without causing unacceptable damage to healthy tissues.

The new work takes an unusual approach. Instead of blocking PFKL, the researchers developed a molecule that activates it. The compound forms a covalent interaction with the enzyme, creating a chemically stable attachment at a specific site on the protein. Covalent drugs can offer prolonged target engagement because the compound remains linked to its target after the initial binding event. That feature may be especially useful for enzymes whose activity needs to be shifted persistently rather than temporarily.

Activating PFKL can push glucose metabolism forward, but increased pathway activity does not necessarily benefit a tumor. Glycolysis is a network governed by tightly balanced flows of carbon, energy and signaling molecules. Driving one control point beyond the range that cancer cells can accommodate may create metabolic stress. Excessive glycolytic activity can alter the levels of upstream and downstream metabolites, disturb cellular energy management and intensify dependence on nutrients or pathways that tumors cannot easily replace.

The reported compound, therefore, appears to exploit a vulnerability created by cancer’s metabolic ambition. Tumor cells may be heavily invested in high-rate glucose consumption, yet that dependence can become a liability when the pathway is forcibly accelerated. A covalent PFKL activator could act like a metabolic accelerator that pushes malignant cells beyond a tolerable operating limit. Rather than starving tumors by removing glucose, the strategy aims to make their existing glucose-processing program harmful to their survival.

This concept is notable because most efforts to target cancer metabolism have focused on inhibition. Blocking glycolysis can reduce ATP production or deprive cells of biosynthetic intermediates, but normal tissues also rely on glucose metabolism, creating potential toxicity concerns. Enzyme activation offers a different therapeutic logic: selectively destabilizing the metabolic state on which tumor cells depend. The success of this approach will depend on how strongly the compound affects PFKL in cancer compared with healthy cells, as well as how different tumor types manage the resulting metabolic pressure.

The study’s title indicates that the activator suppressed tumor growth, a finding that moves the concept beyond biochemical enzyme assays. To establish whether such a molecule can become a practical therapy, researchers will need to define its selectivity, pharmacological behavior, distribution through the body and safety profile. They will also need to determine whether tumors can adapt by reducing glucose uptake, switching to alternative fuels or altering the expression of other glycolytic enzymes. Cancer cells are remarkably capable of rewiring metabolism, and resistance mechanisms will be a central question for future work.

The covalent nature of the compound also makes careful chemical characterization essential. A useful covalent drug must react efficiently with its intended protein while minimizing unwanted modification of other cellular proteins. Researchers typically examine target engagement, proteome-wide selectivity and the durability of the biological response. These studies can reveal whether the compound’s effects arise primarily from PFKL activation or from broader chemical reactivity. If the molecule demonstrates a favorable selectivity profile, it could provide a framework for developing additional covalent activators against metabolic enzymes.

The findings place PFKL in a growing category of drug targets whose therapeutic potential may lie not in shutting them down, but in pushing them into an abnormal state. By turning a central glycolytic control point against cancer cells, the researchers have highlighted a strategy that combines chemical biology with the emerging science of metabolic stress. The work does not mean that a new cancer treatment is immediately available, but it offers a provocative blueprint: sometimes the most effective way to attack a tumor’s fuel system may be to make it burn too intensely to survive.

Subject of Research: Cancer metabolism and covalent activation of phosphofructokinase L (PFKL) to suppress tumor growth

Article Title: A covalent PFKL activator suppresses tumor growth

Article References: Jiang, X., Lynch, E.M., Lyu, C. et al. “A covalent PFKL activator suppresses tumor growth.” Nature Chemical Biology (2026). https://doi.org/10.1038/s41589-026-02289-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41589-026-02289-9

Keywords: cancer metabolism, PFKL, phosphofructokinase, glycolysis, covalent activator, tumor growth, metabolic stress, chemical biology, cancer therapeutics

The study, titled “Selective targeting of cancer and senescence via shared metabolic shifts extends lifespan of old mice,” was led by Zachery R. Robinson, with Irina M. Conboy as corresponding author. Both researchers are affiliated with the Department of Bioengineering and the QB3 Institute at the University of California, Berkeley. Their work addresses a major challenge in aging biology: senescent cells accumulate over time, remain metabolically active and release inflammatory factors known collectively as the senescence-associated secretory phenotype, or SASP. These signals can damage neighboring tissues, promote chronic inflammation and create an environment that supports tumor development.

Senescent cells and cancer cells are biologically different, but many share a critical vulnerability. Their mitochondria and energy-producing pathways are frequently impaired or rewired, leaving them dependent on limited metabolic reserves. Unlike healthy cells, which can often switch between fuel sources when energy production is disrupted, these damaged or rapidly proliferating cells may have little capacity to compensate for a sudden decline in ATP, the molecule that powers most cellular processes. The researchers designed DMA to intensify this energy crisis selectively, pushing vulnerable cells toward apoptosis while allowing healthy cells to preserve their energy balance.

Each component of DMA contributes to the metabolic pressure. Dichloroacetate inhibits pyruvate dehydrogenase kinase, an enzyme that regulates the entry of pyruvate into mitochondrial oxidation and can alter how cells use glucose. Metformin, widely prescribed for type 2 diabetes, can reduce mitochondrial respiratory activity and limit ATP production under certain conditions. Navitoclax blocks anti-apoptotic members of the BCL-2 protein family, lowering the threshold for programmed cell death. Used together, the drugs were intended to weaken energy production and simultaneously remove part of the molecular protection that allows senescent and cancer cells to survive.

The investigators tested DMA in several human cellular systems, including senescent cells generated through different biological mechanisms and cancer cell lines derived from cervical, breast and colorectal tumors. The treatment reduced the viability of these unhealthy cells while sparing healthy primary fibroblasts, neural precursor cells and hepatocytes. Human myoblasts, which develop into muscle cells, were also largely preserved. Notably, the combination affected breast cancer cells that showed relative resistance to navitoclax alone, suggesting that the metabolic agents may increase the effectiveness of the apoptosis-targeting drug.

Laboratory analyses supported the proposed mechanism. DMA caused a pronounced depletion of ATP in senescent and cancer cells, whereas healthy cells were better able to maintain energy production. The researchers concluded that senescent cells lacked sufficient metabolic flexibility to redirect energy generation when the treatment disrupted their normal pathways. This imbalance activated apoptosis and reduced cancer-cell proliferation. The findings suggest that the therapy does not simply identify senescent or malignant cells through a single surface marker; instead, it exploits the functional consequences of mitochondrial dysfunction and altered metabolism.

The team then evaluated DMA in aged mice. In a short-term experiment, animals receiving the combination showed a significantly greater improvement in treadmill running time than control animals treated with solvent. The therapy did not produce a measurable advantage in hanging-test performance, a test of muscular endurance and grip, and it did not significantly alter frailty scores. These results indicate that the immediate functional benefits were selective rather than a broad reversal of every age-related physical deficit. The authors also assessed blood proteins and observed changes in several inflammatory factors associated with the SASP, shifting the circulating profile toward a more youthful pattern.

A longer-term experiment produced the most striking result. Intermittent DMA treatment began when the mice were approximately 18 months old, an age corresponding to advanced adulthood in laboratory animals. After treatment began, the mice receiving DMA lived an average of 102.6 days longer than controls, representing an increase of approximately 41.7 percent in post-treatment survival. The researchers reported no marked thrombocytopenia, the dangerous decline in platelet numbers that has limited the use of conventional high-dose navitoclax. Reducing the navitoclax dose while reinforcing its activity through metabolic stress may therefore be central to the treatment’s apparent tolerability.

The findings remain preliminary and cannot yet establish whether DMA would extend healthy lifespan or treat cancer in humans. The animal survival groups were small, and the experiments did not use mice carrying spontaneous cancers or models that reproduce the full complexity of age-related disease. Additional studies will be needed to determine how the drugs interact over longer periods, whether the treatment affects different organs or tumor types, and whether subtle toxicities emerge with repeated dosing. Even so, the study offers a potentially important framework: rather than targeting cancer and senescence separately, a carefully calibrated metabolic intervention may attack both through their shared dependence on compromised energy systems. With metformin and dichloroacetate already used clinically for other indications, and navitoclax having undergone human testing, the researchers say DMA could provide a practical starting point for future translational research.

Subject of Research: Animals

Article Title: Selective targeting of cancer and senescence via shared metabolic shifts extends lifespan of old mice

News Publication Date: August 3, 2026

Web References: https://doi.org/10.18632/aging.206399; https://www.aging-us.com/figure/206399/f4

References: Robinson Z. R. et al., “Selective targeting of cancer and senescence via shared metabolic shifts extends lifespan of old mice,” Aging-US, published July 17, 2026. DOI: 10.18632/aging.206399

Image Credits: Copyright © 2026 Robinson et al., released under the Creative Commons Attribution License (CC BY 4.0).

Keywords: senescence, cancer, aging, metabolic shift, ATP, senolytics, mitochondria, metformin, dichloroacetate, navitoclax, lifespan extension, cellular metabolism

Cancer cells exhibit distinct metabolic phenotypes compared to normal cells, which has spurred interest in their specific biochemical pathways. The CLIC1-PKM2 axis is positioned at the nexus of crucial metabolic processes, where chloride intracellular channel 1 (CLIC1) interacts with pyruvate kinase isozyme M2 (PKM2). This study meticulously elucidates how this interaction enhances the glycolytic process, allowing cancer cells to thrive under conditions of limited oxygen, a phenomenon known as the Warburg effect. By harnessing these findings, future therapies could aim to disrupt this axis, potentially starving tumor cells of the energy they require to grow and spread.

The findings from this research are particularly significant in the context of gastric cancer, a malignancy notoriously associated with poor prognosis and limited treatment options. The team’s investigations revealed that elevated levels of CLIC1 correspond with aggressive tumor behavior and poor patient outcomes. As such, it raises the tantalizing prospect that CLIC1 could serve as a robust biomarker for gastric cancer, aiding in both diagnosis and the monitoring of disease progression. More importantly, targeting this marker could lead to innovative treatment strategies that enhance therapeutic efficacy.

It’s noteworthy that the classical view of tumor metabolism is being challenged by this new paradigm, with an emphasis on how specific metabolic pathways facilitate tumor growth and survival. The interaction between CLIC1 and PKM2 exemplifies how cancer cells can adapt their metabolism to exploit alternative energy pathways. The study’s authors provide a thorough analysis of this interaction, examining enzymatic activities and downstream metabolic consequences. Understanding these mechanisms at an in-depth biochemical level paves the way for the development of novel inhibitors that could thwart cancer cell proliferation.

Moreover, the study compels us to reconsider existing therapeutic approaches. Current treatments for gastric cancer, such as chemotherapy and targeted therapy, have shown limited successes. By integrating metabolic reprogramming into our therapeutic arsenal, clinicians could personalize treatment options that more effectively combat the unique metabolic needs of gastric tumors. Furthermore, with a focus on the CLIC1-PKM2 axis, researchers may uncover additional vulnerabilities within the metabolic networks of gastric cancer cells that were previously overlooked.

The potential integration of metabolic inhibitors into treatment regimens could herald a new era of precision medicine for gastric cancer patients. By targeting the molecular machinations that drive tumor growth, oncologists may not only enhance the efficacy of existing therapies but may also extend survival rates and improve quality of life. This focus on the metabolic dependencies of cancer cells underscores a paradigm shift in how we approach treatment and opens avenues for innovative research that could lead to breakthrough therapies.

The research also highlights the importance of collaborative efforts across disciplines. The complexities of cancer demand integrative approaches that combine biochemistry, oncology, and molecular biology. Multi-institutional collaborations could facilitate the rapid translation of laboratory findings into clinical applications. The convergence of these fields is vital to unraveling the intricate metabolic networks that sustain cancer, thus accelerating the development of actionable therapies that can combat this disease effectively.

In summary, the investigators provide a compelling case for the involvement of the CLIC1-PKM2 axis in the metabolic rewiring of gastric cancer cells. Their results suggest that by targeting this axis, it may be possible to hinder cancer progression and offer patients new hope for effective treatment. The implications of this research extend beyond the realm of gastroenterology, potentially informing treatment strategies for other malignancies where similar metabolic alterations are observed.

As research efforts continue to unravel the complexities of cancer metabolism, it will be essential to remain vigilant for new therapeutic targets. This study serves as a stepping stone towards understanding metabolic dysregulation in cancer cells, reinforcing the notion that manipulating metabolic pathways could yield significant benefits in cancer therapy. The potential interaction of the CLIC1-PKM2 axis with other metabolic and signaling pathways provides a rich ground for future exploration that could further elucidate the multifaceted nature of gastric cancer.

The immediate future appears promising for those affected by gastric cancer, thanks to the relentless pursuit of researchers dedicated to discovering transformative pathways in cancer metabolism. As we continue to grapple with the challenges posed by this aggressive disease, insights from studies like this one may illuminate new paths forward, enhancing therapeutic strategies and patient outcomes in ways we are only beginning to comprehend. The collaboration between basic and clinical researchers will undoubtedly be imperative in translating these laboratory findings into groundbreaking clinical applications.

In conclusion, the research conducted by Yang, J., Yu, Z., and Feng, Y. lays crucial groundwork for our understanding of the metabolic mechanisms underpinning gastric cancer. The CLIC1-PKM2 axis emerges as a critical player in the orchestration of glycolytic metabolism, substantiating its potential as a target for innovative therapeutic development. This pioneering work opens a new chapter in the ongoing battle against gastric cancer, inspiring hope in patients and clinicians alike.

Subject of Research: Exploration of the CLIC1-PKM2 axis and its role in glycolytic metabolism in gastric cancer progression.

Article Title: The CLIC1-PKM2 axis orchestrates glycolytic metabolism to accelerate gastric cancer progression.

Article References:

Yang, J., Yu, Z., Feng, Y. et al. The CLIC1-PKM2 axis orchestrates glycolytic metabolism to accelerate gastric cancer progression.
J Transl Med (2025). https://doi.org/10.1186/s12967-025-07463-6

Image Credits: AI Generated

DOI: 10.1186/s12967-025-07463-6

Keywords: gastric cancer, CLIC1-PKM2 axis, glycolytic metabolism, cancer progression, metabolic pathways.

Hepatocellular carcinoma stands as one of the most prevalent forms of liver cancer worldwide, with rising incidence rates linked to various risk factors, including chronic liver diseases and viral infections. The metabolic reprogramming of tumor cells has become a cornerstone in cancer biology, influencing not only tumor growth but also impacting the tumor microenvironment. This study investigates the dynamic changes in mitochondrial temperature as a consequence of altered metabolic activity in HepG2 cells, providing a fresh perspective amidst ongoing efforts to understand cancer metabolism.

At the heart of this investigation is the observation that cancer cells often exhibit heightened metabolic rates compared to their non-cancerous counterparts. Mitochondria, the energy powerhouse of the cell, play a pivotal role in this metabolic shift. By regulating ATP production and various biosynthetic pathways, mitochondria contribute to the overall energy homeostasis required for rapid cell proliferation. In this context, the study examines how fluctuations in metabolic activity directly influence mitochondrial temperature, a factor that may serve as a novel biomarker for cancer diagnostics.

The researchers employed advanced imaging techniques to measure mitochondrial temperature changes in real-time within HepG2 cells subjected to varying metabolic conditions. By utilizing tools such as fluorescence resonance energy transfer (FRET) technologies, they were able to derive quantitative measurements that provided unprecedented insights into the thermal dynamics of these cellular organelles. This innovative approach indicates a significant breakthrough in our understanding of mitochondrial function in cancer cells.

In their findings, the authors reported that increased metabolic activity correlates with elevated mitochondrial temperatures, suggesting an intrinsic link between energy utilization and thermal responses within the cell. This correlation further emphasizes the importance of metabolic reprogramming in cancer survival and growth, allowing tumor cells to adapt and thrive even under adverse conditions. This critical insight raises intriguing questions about the potential applications of mitochondrial temperature as a diagnostic marker.

Moreover, the study introduces a compelling narrative about the adaptability of cancer cells. In the face of fluctuating nutrient availability and the need for rapid growth, cells are equipped to alter their metabolic pathways, which in turn affects mitochondrial functions and thermal properties. Understanding these adaptive mechanisms could lead to targeted interventions that disrupt the metabolic flexibility of cancer cells, thereby hindering their ability to thrive.

As the research unfolds, it becomes clear that mitochondrial temperature could serve as a reliable indicator of metabolic alterations in cancer cells. This could revolutionize how we diagnose and monitor hepatocellular carcinoma, shifting from reliance on invasive procedures to potentially using non-invasive imaging techniques that monitor metabolic states in real-time. By offering a window into the cellular landscape of tumors, such diagnostic strategies could enhance precision medicine approaches.

Key to integrating this finding into clinical practice will be the establishment of standardized protocols for measuring mitochondrial temperature across various cancer types. The technical robustness demonstrated in this study serves as a foundation for future research endeavors aimed at exploring the relationship between mitochondrial thermal dynamics and cancer progression in broader contexts.

As the scientific community delves deeper into this frontier, the implications of this research extend beyond mere diagnostics. By elucidating the intricate interactions between metabolism and mitochondrial function, it opens avenues for the development of novel therapeutic agents designed to target metabolic vulnerabilities in cancer cells. Strategies that can selectively inhibit metabolic pathways or modulate mitochondrial function could prove transformative in managing hepatocellular carcinoma and perhaps other malignancies.

The broader impact of this research resonates with ongoing efforts to harness the power of metabolic modulation as a therapeutic strategy. As cancer cells become more adept at evading conventional treatments, the need for innovative approaches that exploit their metabolic weaknesses has never been more urgent. This study serves as a catalyst for such exploration, emphasizing the necessity of collaborative efforts to explore this new dimension of cancer treatment.

In conclusion, the work of Gaser et al. highlights the critical interplay between metabolic activity and mitochondrial temperature in HepG2 cells, presenting a promising avenue for new diagnostic and therapeutic strategies in hepatocellular carcinoma. By bridging the gap between metabolic reprogramming and thermal regulation, this research enriches our understanding of cancer biology and heralds a new era in the fight against cancer, where metabolic profiling could lead to life-saving advancements.

As we anticipate the next steps in this exciting research trajectory, the entire scientific community stands on the cusp of breakthroughs that could transform our approach to cancer diagnosis and therapy. Further investigation will not only validate these findings but also expand their applicability across diverse forms of cancer, promising a future where cancer treatment is more targeted, effective, and humane.

Subject of Research: Metabolic activity and mitochondrial temperature in HepG2 hepatocellular carcinoma cells.

Article Title: Alteration of metabolic activity regulates mitochondrial temperature in diagnosis in HepG2 hepatocellular carcinoma cells.

Article References:
Gaser, O.A., Nasr, M.A., Hussein, A.E. et al. Alteration of metabolic activity regulates mitochondrial temperature in diagnosis in HepG2 hepatocellular carcinoma cells. Sci Rep (2025). https://doi.org/10.1038/s41598-025-02807-0

Image Credits: AI Generated

DOI: 10.1038/s41598-025-02807-0

Keywords: Hepatocellular carcinoma, mitochondrial temperature, metabolic activity, cancer diagnostics, metabolic reprogramming.

Head and neck squamous cell carcinoma (HNSCC) arises from the epithelial cells lining critical regions such as the mouth, throat, and nasal cavity. The malignancy is notoriously difficult to eradicate due to its high propensity for recurrence and resistance to standard therapies like chemotherapy and radiation. These conventional treatments, while sometimes effective, often cause debilitating side effects by damaging healthy cells indiscriminately, underscoring the urgent need for more targeted and less toxic options.

The team’s approach hinges on manipulating a fat molecule called ceramide, which plays essential roles in cell health and death signaling. Ceramides, particularly the subtype C18-ceramide, are found in reduced levels in many head and neck cancers, contributing to their unchecked proliferation. LCL768 is a synthetic analog of ceramide designed to increase C18-ceramide specifically inside the mitochondria of tumor cells. This targeted accumulation initiates mitophagy, a cellular process wherein damaged mitochondria are selectively degraded, effectively cutting off the energy supply vital for cancer cell survival.

Mitophagy, often regarded as a quality control mechanism in healthy cells, becomes a double-edged sword in cancer when forcibly activated by LCL768. As cancer cells rely heavily on mitochondrial function to fulfill their heightened energy demands, the induced mitophagy leads to the systematic dismantling of these energy-producing organelles. This catastrophic energy deficit halts tumor growth and triggers cancer cell death, revealing a metabolic Achilles’ heel that the researchers expertly exploited.

Beyond inducing mitophagy, LCL768 delivers a potent metabolic blow by disrupting the tricarboxylic acid (TCA) cycle, a core component of cellular respiration. The pharmaceutical compound achieves this by depleting fumarate — a key metabolite that fuels energy production within mitochondria. This dual-action mechanism, combining ceramide-mediated mitophagy and fumarate depletion, creates a two-pronged metabolic assault that amplifies the drug’s efficacy and specificity against malignant cells.

The preclinical evaluation of LCL768 involved rigorous testing in mouse models bearing human-derived tumors and in vitro tumor cultures established from patient tissues. The researchers observed a consistent and marked elevation of mitochondrial C18-ceramide following treatment. Correspondingly, the treated tumors exhibited biochemical and structural signs of mitophagy and energy collapse, accompanied by a significant retardation in tumor progression. Crucially, supplementing fumarate to these cancer cells rescued them from LCL768’s effects, reaffirming fumarate’s essential role in cancer metabolism and the drug’s targeted action.

One of the most compelling aspects of this research is the selective toxicity of LCL768. Unlike traditional chemotherapeutics, which often harm both tumor and healthy tissues, LCL768 appeared to spare normal cells in experimental models. This specificity likely stems from the differential reliance on mitochondrial ceramide pathways and fumarate metabolism between cancerous and healthy cells. Healthy cells, less dependent on these pathways, remain largely unaffected, which could translate to reduced side effects in clinical settings.

Dr. Besim Ogretmen, the study’s lead investigator and associate director of Basic Science at MUSC Hollings Cancer Center, expressed optimism about the broader implications of this discovery. “By dismantling the internal energy infrastructure of cancer cells, we’re not only halting their growth but effectively targeting their survival strategy,” he explained. This approach could potentially extend beyond head and neck cancers to other tumor types exhibiting similar metabolic dependencies and reduced ceramide levels.

The discovery also dovetails with the growing appreciation in oncology for therapies that target cancer metabolism and stress-response systems. As tumor cells adapt to hostile environments and evade programmed cell death mechanisms, exploiting their unique metabolic frailties offers a promising route to overcome drug resistance. The innovative use of ceramide analogs like LCL768 exemplifies this strategy, marrying lipid biology with metabolic intervention to yield a potent anti-cancer weapon.

While the findings are currently confined to the preclinical stage, the research team is fervently working to transition LCL768 into clinical trials. Such trials will be critical to evaluate the safety, efficacy, and optimal delivery methods of this novel compound in human patients. The hope is that LCL768 or similar drugs may soon provide new therapeutic options for patients who face limited choices due to resistance or toxicity associated with existing treatments.

This study also features a noteworthy collaboration crossing multiple disciplines, highlighting the vital role of integrated research in tackling complex diseases like cancer. The involvement of specialists in lipidomics, molecular biology, pharmacology, and clinical oncology facilitated a comprehensive understanding of the drug’s mechanisms and potential applications.

In conclusion, the development of LCL768 represents a significant leap in cancer therapeutics, introducing a method that not only targets the tumor’s genetic drivers but also its metabolic machinery. By dual targeting mitochondrial ceramide pathways and essential metabolites like fumarate, this strategy strikes at the core of cancer cell viability. If successful in clinical translation, it may herald a new class of mitochondrial-targeting anti-cancer drugs that offer improved effectiveness with fewer side effects, fundamentally shifting the landscape of cancer treatment.

Subject of Research: Human tissue samples

Article Title: Ceramide-Induced Metabolic Stress Depletes Fumarate and Drives Mitophagy to Mediate Tumor Suppression

News Publication Date: 2-Sep-2025

Web References:

• https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-24-4042/763061/Ceramide-Induced-Metabolic-Stress-Depletes
• https://hollingscancercenter.musc.edu/

References: DOI: 10.1158/0008-5472.CAN-24-4042

Image Credits: Medical University of South Carolina

Keywords: Head and neck cancer, Ceramide signaling, Immunotherapy

Cancer cells primarily generate energy using a metabolic adaptation known as the Warburg effect, in which glucose is fermented into lactate even in the presence of adequate oxygen, favoring rapid ATP production via glycolysis. While this pathway is considered less efficient compared to oxidative phosphorylation, it has been enigmatic why cancer cells depend heavily on this mechanism to fuel their unchecked proliferation and survival. The study led by Associate Professor Akiko Kojima-Yuasa delved deeply into this metabolic paradox by scrutinizing the effects of EMC on tumor cell energy dynamics.

Ethyl p-methoxycinnamate, an ester derivative of cinnamic acid abundant in kencur ginger, was administered to Ehrlich ascites tumor cells to investigate its impact on their energy metabolism. Prior research had demonstrated EMC’s cytostatic properties, but the precise metabolic targets remained undefined. The current research illuminated that EMC’s anticancer efficacy is not primarily mediated by inhibiting glycolysis as previously hypothesized. Instead, the compound acts by suppressing de novo fatty acid synthesis and perturbing lipid metabolism, critical pathways for sustaining ATP production and membrane biosynthesis in proliferating tumor cells.

Upon EMC treatment, tumor cells exhibited a marked decrease in ATP levels, attributable to the downregulation of key enzymes involved in fatty acid biosynthetic processes. Since fatty acids serve as essential building blocks for both energy storage and membrane formation, their synthesis represents a vital facet of cancer cell metabolic reprogramming. By disrupting this lipid-centric metabolic axis, EMC imposes an energy crisis that impairs tumor growth and viability.

Interestingly, despite the inhibition of fatty acid synthesis, cancer cells responded by upregulating glycolytic flux, presumably as a compensatory survival mechanism to offset the energy deficit. This metabolic plasticity underscores the complexity of cancer cell bioenergetics and suggests that the Warburg effect alone does not capture the entirety of tumor metabolism. The observed glycolytic increase may reflect cellular attempts to adapt and resist complete metabolic collapse, highlighting the resilience of cancer cells in hostile environments.

However, this compensatory glycolytic surge did not culminate in cell death, indicating that EMC’s mode of action induces cytostatic rather than cytotoxic effects. This is a crucial nuance, as it suggests that while EMC impairs tumor growth by metabolic interference, it may need to be combined with other therapies to achieve full tumor eradication. Nonetheless, its ability to selectively impede lipid synthesis in cancer cells while triggering adaptive glycolysis reveals an exploitable metabolic vulnerability.

This paradigm-shifting insight not only augments the understanding of the Warburg effect but also expands the conceptual framework of cancer metabolism, emphasizing the importance of lipid pathways alongside glucose processing. It prompts a reevaluation of metabolic targets for anticancer drug development, encouraging exploration of agents that degrade fatty acid biosynthetic machinery or modulate lipid homeostasis.

Professor Kojima-Yuasa noted that these findings lay foundational groundwork for identifying new therapeutic targets that transcend conventional glycolytic intervention strategies. As tumor cells rely heavily on fatty acid metabolism for energy and structural components, compounds like EMC could form the basis of next-generation treatments aimed at starving cancer cells through metabolic sabotage.

Moreover, the study highlights the potential significance of natural products such as EMC as bioactive compounds capable of modulating complex biochemical networks within cancer cells. Natural metabolites derived from plants have historically inspired pharmacological breakthroughs, and EMC’s newly discovered role reaffirms the vast untapped therapeutic potential present in nature’s chemical repertoire.

Beyond biochemical implications, this research illustrates the power of integrating experimental cell biology with metabolic studies to elucidate intricate cellular processes. The assays demonstrated that the suppression of ATP generation did not arise from blocking classic glycolysis but rather from interference in specific lipid synthesis pathways, a revelation that could shift the focus of future cancer metabolism research.

As cancers exhibit remarkable heterogeneity in their metabolic profiles, targeting multiple metabolic nodes is likely necessary to overcome resistance mechanisms. EMC represents a promising lead compound that, by impairing fatty acid biosynthesis, could be synergized with other metabolic inhibitors to deliver potent antitumor effects.

In conclusion, Osaka Metropolitan University’s pioneering work on EMC provides compelling evidence that cancer metabolism is more multifaceted than previously understood and that fatty acid synthesis is a critical, druggable aspect of tumor biology. The shift from an exclusive focus on glycolysis to a broader interpretation encompassing lipid metabolism heralds new frontiers in oncology research and therapeutic innovation.

Subject of Research: Cells
Article Title: Ethyl p-methoxycinnamate inhibits tumor growth by suppressing of fatty acid synthesis and depleting ATP
News Publication Date: 2-May-2025
Web References: http://dx.doi.org/10.1038/s41598-025-00131-1
Image Credits: Osaka Metropolitan University
Keywords: ethyl p-methoxycinnamate, kencur ginger, cancer metabolism, Warburg effect, ATP depletion, fatty acid synthesis, lipid metabolism, tumor growth inhibition, metabolic plasticity, glycolysis compensatory response, natural product anticancer agents

At the heart of this groundbreaking research is an innovative technology called SC-pSILAC, which stands for Single-Cell pulsed Stable Isotope Labeling by Amino acids in Cell culture. This method empowers scientists to quantify and analyze protein turnover—the balance between protein production and degradation—within individual cells. This capability surpasses previous ensemble approaches, which averaged protein data across millions of cells and masked cellular heterogeneity.

Prior methods for studying proteins often relied on bulk cell populations, obscuring vital distinctions between dividing and non-dividing cells. This differentiation is crucial particularly in the study of cancer, where rapidly proliferating cells are typically targeted therapies, while quiescent, non-dividing cells frequently evade treatment. SC-pSILAC breaks new ground by enabling the examination of protein dynamics within these distinct cellular states, revealing previously undetectable activities.

One of the key revelations from this technology is that non-dividing cancer cells remain metabolically active, sustaining their influence on the tumor microenvironment even while evading conventional chemotherapy. Detecting and understanding these resilient populations is essential for developing more effective cancer treatments and overcoming therapeutic resistance.

The study also delved into how specific drugs modulate protein turnover in individual cells. Using the proteasome inhibitor bortezomib, widely used in multiple myeloma and other cancers, researchers tracked shifts in protein abundance and stability. The results exposed new proteins and biological pathways affected by the drug, potentially illuminating novel targets for therapy refinement.

By quantifying protein turnover rates with unparalleled resolution, the researchers have effectively opened a window into the life cycle of proteins inside single cells. This knowledge is pivotal for unraveling the molecular basis of diseases characterized by dysfunctional protein homeostasis, such as neurodegeneration and cancer, where the delicate balance of synthesis and degradation is disrupted.

Moreover, the implications of this research stretch beyond disease. Understanding protein stability in aging cells could unlock strategies to promote healthy aging and longevity. As cells age, changes in protein turnover can impair cellular function and resilience. SC-pSILAC provides a powerful tool to systematically map these changes across various cell types and tissues.

Professor Jesper Velgaard Olsen, lead scientist on the project, emphasizes the transformative nature of their approach. "We have developed a technology allowing us to dissect the proteome of single cells with unprecedented depth and precision. Now, we can pinpoint exactly which proteins are present, in what amounts, and how quickly they turn over," he explains. This is a leap forward in proteomics and cellular biology.

The method’s sensitivity also allows for the tracking of metabolic activity in cells that were previously challenging to study. For example, dormant or slow-cycling cells within tumors or tissues can be analyzed to understand their protein dynamics, shedding light on their roles in health and disease states. This level of detail paves the way for personalized medicine approaches that tailor treatments based on the unique protein dynamics of a patient’s cells.

The publication of this work in the prestigious journal Cell signals its significant impact on the scientific community. As experimental techniques continue to evolve, tools like SC-pSILAC may become standard for investigating protein function in real time at the single-cell level. Integration with other omics technologies could further enhance our holistic understanding of cellular biology.

Looking ahead, such advancements could reshape drug development paradigms by identifying protein turnover signatures predictive of drug response or resistance. By mapping the proteomic landscape within individual cells, researchers can design therapies that more precisely target dysfunctional pathways, improving efficacy and reducing side effects.

This pioneering study not only raises the bar for protein research but also ignites hope for breakthroughs in combating diseases that hinge on protein dysregulation. As we edge closer to decoding the proteomic fingerprint of life’s smallest units, the potential for novel diagnostics, therapies, and ultimately cures grows exponentially.

The capabilities provided by SC-pSILAC emphasize the importance of single-cell analysis in modern biomedical research. Moving beyond average measurements to embrace cellular diversity could finally answer pressing questions in cancer biology, neurodegeneration, immunology, and aging. With each probe into the protein turnover dynamics, science steps closer to unraveling the complexity of life itself.

Subject of Research: Cells
Article Title: Global analysis of protein turnover dynamics in single cells
News Publication Date: 31-Mar-2025
Web References: 10.1016/j.cell.2025.03.002
References: Research article published in Cell, March 2025
Keywords: Protein turnover, single-cell proteomics, SC-pSILAC, cancer therapy, proteasome inhibition, cellular metabolism, protein dynamics, drug resistance, aging cells, personalized medicine

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, and despite advances in treatment modalities, effective targeted therapies are still urgently sought. Central to cancer cell survival and rapid proliferation is the increased demand for glucose, a primary energy source. GLUT1, a transmembrane protein facilitating glucose uptake, is notoriously upregulated in many cancers, including CRC, driving enhanced glycolytic metabolism, often referred to as the "Warburg effect." Targeting GLUT1, therefore, has emerged as a logical strategy to deprive tumor cells of their metabolic fuel.

The investigative team employed multiple human colorectal cancer cell lines, including HCT116, DLD1, COLO205, LoVo, and Caco-2, to dissect the anti-proliferative effects of BAY-876. Their in vitro experiments demonstrated that BAY-876 treatment caused a marked inhibition of cell proliferation in several cell lines, suggesting broad efficacy across different CRC subtypes. Notably, GLUT1 protein expression levels declined significantly following treatment, corroborating the drug’s intended mechanism of action.

Delving deeper into the metabolic consequences of GLUT1 inhibition, the researchers conducted flux analyses to monitor changes in cellular respiration. Unexpectedly, despite glucose uptake suppression, treated cells exhibited enhanced mitochondrial respiration. This metabolic shift appeared to be a cellular attempt to compensate for diminished glycolysis. However, this upregulation of mitochondrial activity was accompanied by a surge in reactive oxygen species (ROS), toxic molecules known to inflict oxidative damage within cells.

The accumulation of ROS, precipitated by mitochondrial hyperactivity, led to an increase in apoptosis rates among the colorectal cancer cells. By inducing programmed cell death, BAY-876 effectively undermined tumor cell viability. Western blot assays reinforced these observations, revealing diminished GLUT1 expression and confirming the drug’s impact on critical metabolic pathways.

Perhaps most compelling was the in vivo validation of BAY-876’s anti-cancer potential. Through the establishment of a mouse xenograft model implanted with HCT116 CRC cells, the treatment regimen demonstrated significant tumor growth inhibition. Not only were the tumors smaller in BAY-876-treated animals, but the suppressed GLUT1 expression within these tumors underscored the drug’s targeted efficacy.

The findings of this study illuminate the intricate interplay between cancer metabolism and therapeutic intervention. By inhibiting GLUT1, BAY-876 disrupts the glucose-dependent metabolic machinery that CRC cells rely on, forcing these cells into heightened mitochondrial respiration that ultimately proves cytotoxic. This metabolic vulnerability presents a novel therapeutic window that could be exploited for more effective colorectal cancer treatments.

The research bears significant clinical implications, particularly given the often limited success of conventional chemotherapies in advanced CRC. BAY-876’s ability to selectively target metabolic pathways, alongside evidentiary support from both cellular and animal models, raises hope for a new class of metabolism-focused anti-cancer drugs.

Furthermore, the study enhances our fundamental understanding of cancer cell bioenergetics, suggesting that metabolic plasticity—while a survival advantage for tumors—can be a double-edged sword. The forced switch to mitochondrial respiration, under GLUT1 inhibition, acts as a “metabolic trap,” amplifying ROS production beyond manageable levels, triggering apoptosis.

Importantly, these discoveries open avenues for combinatorial approaches where BAY-876 might be paired with other agents that either heighten oxidative stress or further block metabolic adaptations, potentially amplifying the anti-tumor response while circumventing resistance mechanisms.

While this study focused on colorectal cancer, the implications may well extend to other GLUT1-overexpressing tumors. Prior studies have already reported BAY-876’s efficacy in ovarian and breast cancers, and this latest research adds robust data for colorectal malignancies, broadening the scope of application.

Future investigations will need to address long-term safety, optimal dosing strategies, and potential effects on normal tissues that also express GLUT1. However, the specificity of BAY-876 for cancer cells, combined with the metabolic dependence of tumors, presents a favorable therapeutic index.

This research not only highlights the therapeutic potential of GLUT1 inhibition but also exemplifies the power of targeting cancer metabolism—a burgeoning field that may revolutionize oncologic practice in the coming decades. Inhibiting metabolic pathways critical to tumor survival while sparing normal cells is an attractive paradigm demanding intense scientific focus.

In summary, BAY-876 emerges as a strong candidate for targeted colorectal cancer therapy by selectively disrupting glucose uptake, inducing lethal metabolic stress, and triggering apoptotic cell death in tumor cells. The translational promise is clear, and if clinical trials bear out these preclinical results, BAY-876 could usher in a new era of metabolism-centered cancer treatment.

As we continue to uncover the metabolic vulnerabilities of cancer cells, agents like BAY-876 epitomize the future of personalized, mechanism-based oncology. Selectively cutting off nutrient supply lines and exploiting metabolic imbalances may prove to be one of the most effective strategies yet devised to combat treatment-resistant cancers.

This insightful study underscores the critical importance of glucose metabolism in colorectal cancer progression and provides a beacon of hope for patients through innovative targeted therapies. With continued research and clinical validation, BAY-876 may soon translate from lab bench to frontline clinical use, offering a powerful new weapon against one of the world’s deadliest cancers.

Subject of Research: GLUT1 inhibition and metabolic effects in human colorectal cancer cells

Article Title: GLUT1 inhibition by BAY-876 induces metabolic changes and cell death in human colorectal cancer cells

Article References:
Hayashi, M., Nakamura, K., Harada, S. et al. GLUT1 inhibition by BAY-876 induces metabolic changes and cell death in human colorectal cancer cells. BMC Cancer 25, 716 (2025). https://doi.org/10.1186/s12885-025-14141-9

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14141-9